|
| Press Releases |
|
 |
|
| Tuesday, March 17, 2026 |
|
|
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") has announced the establishment of Eisai Global Capability Centre (EGCC) within Eisai Knowledge Centre, India, in Visakhapatnam (Vizag), Andhra Pradesh, India. more info >> |
|
| Thursday, March 12, 2026 |
|
|
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it is launching an initiative to raise public awareness of the importance of sleep in collaboration with the smartphone application "Pokemon Sleep" more info >> |
|
|
エーザイ、『Pokemon Sleep』とのコラボレーションで眠りの大切さを広く伝える啓発活動を開始 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、スマートフォン向けアプリ『Pokémon Sleep』とのコラボレーションを通じて、眠りの大切さを広く伝える啓発活動に取り組むことをお知らせします。 more info >> |
|
| Wednesday, March 11, 2026 |
|
|
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab, Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD(TM) 2026) from March 17-21, in Copenhagen, Denmark, and online. more info >> |
|
|
エーザイ、アルツハイマー・パーキンソン病学会（AD/PD 2026）において、レカネマブの長期実臨床治療をはじめとするアルツハイマー病の最新知見を発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下エーザイ）は、2026 年 3 月17 日から 21 日にかけてデンマーク コペンハーゲンおよびバーチャルで開催される第 20 回アルツハイマー病・パーキンソン病学会（International Conference on Alzheimer's and Parkinson's Diseasesand related neurological disorders：AD/PD™ 2026）において、抗アミロイド β（Aβ）プロトフィブリル抗体レカネマブ（一般名、製品名「レケンビ®」）を含む、当社のアルツハイマー病（AD）領域の研究成果として、3 件の口頭発表を含む６件の発表を行うとともに、1 件のシンポジウムを主催することをお知らせします。 more info >> |
|
| Monday, March 2, 2026 |
|
|
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) |
| Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG(R) (belzutifan), Merck & Co., Inc., Rahway, NJ, USA's first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor, plus LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. more info >> |
|
|
エーザイとMerck & Co.,Inc.、「レンビマ(R)」（レンバチニブ）と「ウェリレグ(R)」（ベルズチファン）の併用療法が治療歴のある進行腎細胞がんにおいて、カボザンチニブと比較して、疾患進行または死亡のリスクを30％低減 |
| エーザイ株式会社とMerck & Co.,Inc., Rahway, NJ, USA（北米以外ではMSD）は、このたび、エーザイ創製の経口チロシンキナーゼ阻害剤「レンビマ(R)」（一般名：レンバチニブメシル酸塩）とMerck & Co., Inc., Rahway, NJ, USAのファースト・イン・クラスの経口低酸素誘導因子2アルファ（HIF-2α）阻害剤「ウェリレグ(R)」（一般名：ベルズチファン）の経口2剤による併用療法について、抗PD-1/L1療法治療中または治療後に疾患が増悪した進行腎細胞がん（RCC）の治療として評価した臨床第III相LITESPARK-011試験の結果を、2026年米国臨床腫瘍学会（ASCO）泌尿器がん（GU）シンポジウムにおいてLatebreaking口頭アブストラクト（抄録 #LBA417）として発表したことをお知らせします。 more info >> |
|
| Monday, February 16, 2026 |
|
|
エーザイ、新規オレキシン受容体作動薬 E2086 が日本において、ナルコレプシーを対象として、厚生労働省より希少疾病用医薬品に指定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、自社創製の新規選択的オレキシン 2 受容体作動薬 E2086 について、予定される効能又は効果であるナルコレプシーを対象として、厚生労働省より希少疾病用医薬品（オーファンドラッグ）に指定されたことをお知らせします。 more info >> |
|
|
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received an orphan drug designation for its in-house discovered and developed novel selective orexin 2 receptor agonist E2086, with prospective indication for narcolepsy, from the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Tuesday, February 10, 2026 |
|
|
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of "LEQEMBI(R)" (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
FILMART and EntertainmentPulse 2026 open today
Mar 18, 2026 17:30 JST
|
|
|
AdsDrama Introduces Short Drama Advertising Platform Amid Growth in Digital Content Monetization
Mar 18, 2026 15:30: JST
|
|
|
AdsDrama Introduces Short Drama Advertising Platform Amid Growth in Digital Content Monetization
Mar 18, 2026 14:30 HKT/SGT
|
|
|
三菱重工、新しい経営方針「ITO」の実践による優秀事例を顕彰
Mar 18, 2026 14:00: JST
|
|
|
GUOQUAN FOOD (2517.HK) Surging core operating profit, Four Stores Jointly Advancing with Concerted Efforts for Long-Term Growth
Mar 18, 2026 13:54 HKT/SGT
|
|
|
Chuangxin Industries Announces 2025 Annual Results
Mar 18, 2026 09:30 HKT/SGT
|
|
|
創新實業公佈2025年全年業績 收入及利潤穩步增長
Mar 18, 2026 09:00 HKT/SGT
|
|
|
创新实业公布2025年全年业绩 收入及利润稳步增长
Mar 18, 2026 00:04 HKT/SGT
|
|
|
Maxon、リアルタイム建築ビジュアライゼーションソリューションでAEC市場に正式参入
Mar 17, 2026 23:05: JST
|
|
|
Maxon, 실시간 Archviz 솔루션으로 AEC 시장 공식 진출
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon推出即時Archviz解決方案，正式進軍AEC市場
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon推出实时Archviz解决方案，正式进军AEC市场
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution
Mar 17, 2026 22:05 HKT/SGT
|
|
|
FinHarbor Introduces Rapid-Deployment Neobank Platform for 30-Day Go-Live
Mar 17, 2026 22:00: JST
|
|
|
FinHarbor Introduces Rapid-Deployment Neobank Platform for 30-Day Go-Live
Mar 17, 2026 22:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
